Literature DB >> 9414193

Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases.

K A Iczkowski1, G T MacLennan, D G Bostwick.   

Abstract

Prostate needle biopsies occasionally contain an atypical small acinar proliferation (ASAP) that is suspicious for, but not diagnostic of, adenocarcinoma. The histologic features and clinical significance of this finding are unexplored. We evaluated 33 cases of ASAP with at least one follow-up needle biopsy seen at Mayo Clinic from 1993 to 1996. Numerous histologic and clinical features were assessed to determine their predictive value for adenocarcinoma on subsequent biopsy. Mean patient age was 61.6 years (range 45-72). Adenocarcinoma was identified on follow-up biopsy in 15 of 33 patients (45%), with a median follow-up of 9 months (range 1-27). Gleason score varied from 4 to 7 (mean 5.9). Two patients (6%) had subsequent diagnoses of ASAP after one and three repeat biopsies. Digital rectal examination, serum prostate-specific antigen, and a variety of histologic findings were not predictive of cancer on follow-up biopsy. These histologic findings included number of biopsy cores (mean 5.5), number of acini per focus of ASAP (mean 7.9), number of foci (mean one), variation in acinar size, nuclear enlargement (none, 12% of cases; mild, 45%; moderate, 33%; severe, 10%), nucleolar enlargement (none, 27%; mild, 46%; moderate, 27%), luminal mucin (39%), crystalloids (6%), focal chronic inflammation (64%), adjacent atrophy (100%), and adjacent high-grade prostatic intraepithelial neoplasia (PIN) (42%). Stratification of suspicion in cases of ASAP without PIN into three categories ("favor benign, uncertain, and favor carcinoma") was somewhat predictive of subsequent cancer (20%, 25%, and 60% of cases with subsequent cancer, respectively), but the results were not significant. The high predictive value of ASAP for subsequent adenocarcinoma warrants repeat biopsy. No single clinical or pathologic feature appeared to increase the likelihood of subsequent cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414193     DOI: 10.1097/00000478-199712000-00012

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

Review 1.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

2.  Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials.

Authors:  Naoto Kuroda; Kazunobu Katto; Masato Tamura; Tomoyuki Shiotsu; Shoichiro Nakamura; Yuji Ohtsuki; Ondrej Hes; Michal Michal; Kaori Inoue; Masahiko Ohara; Keiko Mizuno; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2010-09-21       Impact factor: 2.309

3.  CUA guidelines on prostate biopsy methodology.

Authors:  Assaad El-Hakim; Sabri Moussa
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

4.  Proliferative lesions of prostate: a multivariate approach to differential diagnosis.

Authors:  Fernanda de Barros Correia Cavalcanti; Venâncio Avancini Ferreira Alves; Julio Pereira; Cristina T Kanamura; Alda Wakamatsu; Luís Balthazar Saldanha
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

5.  Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens.

Authors:  Kitty Pavlakis; Konstantinos Stravodimos; Theodoros Kapetanakis; Alkiviadis Gregorakis; Sofia Athanassiadou; Olympia Tzaida; Constantinos Constantinides
Journal:  Int Urol Nephrol       Date:  2009-08-05       Impact factor: 2.370

Review 6.  Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy.

Authors:  Jeffrey J Tosoian; Ridwan Alam; Mark W Ball; H Ballentine Carter; Jonathan I Epstein
Journal:  Nat Rev Urol       Date:  2017-08-31       Impact factor: 14.432

7.  Drug therapies for eradicating high-grade prostatic intraepithelial neoplasia in the prevention of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2005

8.  Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002.

Authors:  Matthew B Gretzer; Alan W Partin
Journal:  Rev Urol       Date:  2003

9.  [Histopathology reports of findings of prostate needle biopsies. Individual treatment].

Authors:  I Damjanoski; J Müller; T J Schnöller; R Küfer; L Rinnab
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

10.  High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancer.

Authors:  Debra L Zynger; Ximing Yang
Journal:  Int J Clin Exp Pathol       Date:  2008-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.